These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
390 related articles for article (PubMed ID: 15750033)
21. Characterization of the in vitro activity of novel lipoglycopeptide antibiotics. Arhin FF; Belley A; McKay GA; Moeck G Curr Protoc Microbiol; 2010 Feb; Chapter 17():Unit17.1. PubMed ID: 20131224 [TBL] [Abstract][Full Text] [Related]
22. Origin, structure, and activity in vitro and in vivo of dalbavancin. Malabarba A; Goldstein BP J Antimicrob Chemother; 2005 Mar; 55 Suppl 2():ii15-20. PubMed ID: 15750032 [TBL] [Abstract][Full Text] [Related]
23. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725 [TBL] [Abstract][Full Text] [Related]
24. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci. Huang V; Brown WJ; Rybak MJ Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134 [TBL] [Abstract][Full Text] [Related]
25. Experimental study on the efficacy of combinations of glycopeptides and beta-lactams against Staphylococcus aureus with reduced susceptibility to glycopeptides. Domenech A; Ribes S; Cabellos C; Taberner F; Tubau F; Domínguez MA; Montero A; Liñares J; Ariza J; Gudiol F J Antimicrob Chemother; 2005 Oct; 56(4):709-16. PubMed ID: 16120625 [TBL] [Abstract][Full Text] [Related]
26. Susceptibility of methicillin-resistant Staphylococcus aureus to vancomycin, teicoplanin, linezolid, pristinamycin and other antibiotics. Samra Z; Ofer O; Shmuely H Isr Med Assoc J; 2005 Mar; 7(3):148-50. PubMed ID: 15792257 [TBL] [Abstract][Full Text] [Related]
27. Vancomycin resistance: are there better glycopeptides coming? Linden PK Expert Rev Anti Infect Ther; 2008 Dec; 6(6):917-28. PubMed ID: 19053904 [TBL] [Abstract][Full Text] [Related]
28. Selection of resistance to glycopeptide antibiotics in staphylococci. Biavasco F; Giovanetti E; Varaldo PE J Chemother; 1991 Jan; 3 Suppl 1():166-8. PubMed ID: 12041756 [TBL] [Abstract][Full Text] [Related]
29. A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp. Drago L; Nicola L; De Vecchi E Clin Microbiol Infect; 2008 Jun; 14(6):608-11. PubMed ID: 18397336 [TBL] [Abstract][Full Text] [Related]
30. [In vitro study of strains of Staphylococcus: choice of an antibiotic]. Messmer JC; Lecaillon-Thibon E; Soler H Sem Hop; 1984 May; 60(19):1329-32. PubMed ID: 6326323 [TBL] [Abstract][Full Text] [Related]
31. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates]. Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069 [TBL] [Abstract][Full Text] [Related]
32. [Methicillin resistant Staphylococcus aureus and glycopeptides (vancomycin, teicoplanin): in vitro selection of resistance]. Serazin V; Mougeot C; Libert JM Pathol Biol (Paris); 1994 Apr; 42(4):323-7. PubMed ID: 7808785 [TBL] [Abstract][Full Text] [Related]
33. Spectrum and potency of dalbavancin tested against 3322 Gram-positive cocci isolated in the United States Surveillance Program (2004). Jones RN; Stilwell MG; Sader HS; Fritsche TR; Goldstein BP Diagn Microbiol Infect Dis; 2006 Feb; 54(2):149-53. PubMed ID: 16426793 [TBL] [Abstract][Full Text] [Related]
34. Comparative bactericidal activities of daptomycin, glycopeptides, linezolid and tigecycline against blood isolates of Gram-positive bacteria in Taiwan. Huang YT; Liao CH; Teng LJ; Hsueh PR Clin Microbiol Infect; 2008 Feb; 14(2):124-9. PubMed ID: 18076671 [TBL] [Abstract][Full Text] [Related]
35. Clinical isolates of Staphylococcus aureus from 1987 and 1989 demonstrating heterogeneous resistance to vancomycin and teicoplanin. Rybak MJ; Cha R; Cheung CM; Meka VG; Kaatz GW Diagn Microbiol Infect Dis; 2005 Feb; 51(2):119-25. PubMed ID: 15698717 [TBL] [Abstract][Full Text] [Related]
36. Dalbavancin, a long-acting lipoglycopeptide for the treatment of multidrug-resistant Gram-positive bacteria. Decousser JW; Bourgeois-Nicolaos N; Doucet-Populaire F Expert Rev Anti Infect Ther; 2007 Aug; 5(4):557-71. PubMed ID: 17678421 [TBL] [Abstract][Full Text] [Related]
37. In vitro activity of oxacillin, vancomycin and teicoplanin against staphylococci isolated from patients on surgical and coronary intensive care units. Kucukates E; Nalan Karayel E; Gultekin N; Okuyan E; Kansiz E; Gurler N Int J Antimicrob Agents; 2004 Aug; 24(2):193-4. PubMed ID: 15288323 [No Abstract] [Full Text] [Related]
38. Clinical relevance of increasing glycopeptide MICs against Staphylococcus aureus. Gould IM Int J Antimicrob Agents; 2008 Apr; 31 Suppl 2():1-9. PubMed ID: 18485997 [TBL] [Abstract][Full Text] [Related]
39. Glycopeptides: Update on an old successful antibiotic class. Pace JL; Yang G Biochem Pharmacol; 2006 Mar; 71(7):968-80. PubMed ID: 16412985 [TBL] [Abstract][Full Text] [Related]
40. [Determination of the in vitro activity of 2 glycopeptides (vancomycin and teicoplanin) against methicillin-resistant Staphylococcus aureus of intrahospital origin]. Gil M; Otth L; Wilson M; Arce E; Zaror A; Lizama V Rev Med Chil; 2000 Jan; 128(1):111-2. PubMed ID: 10883531 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]